

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
10 September 2020 (10.09.2020)



(10) International Publication Number  
**WO 2020/180356 A1**

(51) International Patent Classification:

A61K 31/5685 (2006.01) A61P 9/00 (2006.01)  
A61K 45/06 (2006.01) A61P 9/04 (2006.01)

(21) International Application Number:

PCT/US2019/060961

(22) International Filing Date:

12 November 2019 (12.11.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/814,149 05 March 2019 (05.03.2019) US

(71) Applicant: **WINDTREE THERAPEUTICS, INC.**  
[US/US]; 2600 Kelly Road, Warrington, Pennsylvania  
18976 (US).

(72) Inventors: **BIANCHI, Giuseppe**; Piazza Adigrat 4, 20133  
Milano (IT). **FERRARI, Patrizia**; Gasparotto 57A, 21100  
Varese (IT). **FERRANDI, Mara**; Via Cenisio 34, 20100  
Milano (IT). **BARRASSI, Paolo**; Via Campagnetta 6/B,  
21010 Castelveccana (VA) (IT).

(74) Agent: **REED, Janet E.** et al.; Potter Anderson and Cor-  
roon LLP, 1313 N. Market Street, Wilmington, Delaware  
19801 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,


AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,  
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,  
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: **ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF)**



**FIG. 1**

(57) Abstract: Compositions for intravenous infusion of istaroxime, or a metabolite of istaroxime, in human patients suffering from heart failure are disclosed. Likewise, methods for extended infusion of istaroxime or its metabolites in individuals with heart failure are disclosed. In particular, some methods disclosed herein include the infusion of istaroxime, or a metabolite thereof, for a period of time that is greater than six hours in order to improve cardiac relaxation without triggering arrhythmogenic events in an individual suffering from heart failure. Other methods include administration of istaroxime until certain plasma concentration thresholds of istaroxime metabolites are achieved. Also disclosed are istaroxime metabolites with selective SERCA2a activation.



WO 2020/180356 A1